Post

Friedreich’s ataxia: major trial readouts and regulatory events to watch in 2023

The FDA could approve the first treatment for Friedreich’s ataxia, and at least three other major trials have readouts expected by year end.

Autobahn begins dosing in Phase I major depressive disorder treatment trial

An oral TRβ agonist, ABX-002 had shown target engagement in areas of the brain linked to depression.

VIDA introduces updated platform for clinical trial imaging operations

The platform has been launched to accelerate the onboarding of clinical trial sites.

Exscientia receives approval to begin advanced solid tumour therapy trial

The trail will assess EXS-21546 along with anti-PD-1 therapy in relapsed or refractory RCC and NSCLC patients.

Cancer Research UK and Stitch to pilot app for patients in trials

Trialmap helps participants to view data on the trial and receive reminders for appointments.